Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1999-03-10
2000-03-28
Chang, Ceila
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
546186, 546187, 546188, 546189, A61K 31445, C07D40102
Patent
active
060432551
ABSTRACT:
Di-N-substituted piperazine or 1,4 di-substituted piperadine compounds in accordance with formula I (including all isomers, salts, esters, and solvates) ##STR1## wherein R, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.21, R.sup.27, R.sup.28, X, Y, and Z are as defined herein are muscarinic antagonists useful for treating cognitive disorders such as Alzheimer's disease. Pharmaceutical compositions and methods of preparation are also disclosed. Also disclosed are synergistic combinations of compounds of the above formula with acetylcholinesterase inhibitors.
REFERENCES:
patent: 2792398 (1957-05-01), Kyrides
patent: 2819273 (1958-01-01), Drain et al.
patent: 3772298 (1973-11-01), Bartman et al.
patent: 3852455 (1974-12-01), Carr
patent: 3988456 (1976-10-01), Nishimura et al.
patent: 4066070 (1978-01-01), Sukai et al.
patent: 4251655 (1981-02-01), Scott et al.
patent: 4525358 (1985-06-01), Balter et al.
patent: 4757074 (1988-07-01), Coker et al.
patent: 4895841 (1990-01-01), Sugimoto et al.
patent: 5010078 (1991-04-01), Abou-Gharbia et al.
patent: 5100901 (1992-03-01), Sugimoto et al.
patent: 5318967 (1994-06-01), Bruderer et al.
patent: 5700801 (1997-12-01), Pieper et al.
patent: 5837707 (1998-11-01), Perregaard et al.
patent: 5900422 (1999-05-01), Ali
Jeidrich et al. "Pharmacotheraphy of alzheimer dementia: therapy of cognitive . . . " MEDLINE 97247715, 1997.
Chopin et al. "Effects of four non-cholinergic cognitive enhancers . . . " BIOSIS 93057018, 1992.
Baumgold, et al., European Journal of Pharmacology 251 (1994) 315-317.
Melchiorre, et al., J. Med. Chem, 1993, 36 3734-3737.
Doods, et al., Life Sciences, vol. 52, pp. 497-503 (1993).
Eberlien, et al., Trends in Pharmacol Sci Dec. 1989 p 50-54.
Borroni, et al., Biochem Soc, Trans, Aug. 1994, 22(3) p. 755-758.
Logemann, et al., Brit. J. Pharmacol (1961) 17, 286-296.
Wilkerson et al, J. Med. Chem., 36 (20) (1993), p. 2899-2907.
Vidaluc et al, J. Med. Chem., 37 (5) (1994), p. 689-698.
Drukarch et al, Eur. J. Pharmacol., 141 (1-2) (1987), p. 153-157.
Provan et al, Brit. J. Pharmacol., 111 (4) (1994), p. 1103-1110.
Cheng et al, Biochem. Pharmacol., 22 (1973), p. 3099-3108.
Watson et al, J. Pharmacol. Exp. Ther., 237 (1986), p. 411-418.
Chemical Abstracts, 49, 1 (1955), abstract 322b.
Chemical Abstracts, 70, 21 (1969), abstract 96754t.
Dankwardt et al, Tet. Let., 36, 28 (1995), p. 4923-4926.
Protiva et al, Collect. Czech. Chem. Commun., 40, 12 (1975), p. 3904-3923.
Chemical Abstracts, 53, abstract 20096f (1959).
Chemical Abstracts, 53, abstracts 12306f and 12307d (1959).
Chemical Abstracts, 53, abstract 9254b (1959).
Chemical Abstracts, 53, abstract 8172b (1959).
Chemical Abstracts, 81, abstract 136178 (1972).
Chemical Abstracts, vol. 45, No. 12 (1951) 5153, Ochiai et al, "Electrolytic reduction of the pyridinium ion."
Asberom Theodros
Barnett Allen
Berger Joel G.
Boyle Craig D.
Browne Margaret E.
Chang Ceila
Magatti Anita W.
Schering Corporation
LandOfFree
Muscarinic antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Muscarinic antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Muscarinic antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1326312